Name | enzaplatovir |
---|---|
Synonyms |
OZ40XB915E
UNII:OZ40XB915E enzaplatovir 1H,5H-Imidazo[1,2-a]pyrrolo[1,2-d]pyrazin-5-one, 2,3,10,10a-tetrahydro-1-[(3-methyl-4-isoxazolyl)carbonyl]-10a-(6-methyl-3-pyridinyl)-, (10aR)- (10aR)-1-[(3-Methyl-1,2-oxazol-4-yl)carbonyl]-10a-(6-methyl-3-pyridinyl)-2,3,10,10a-tetrahydro-1H,5H-imidazo[1,2-a]pyrrolo[1,2-d]pyrazin-5-one |
Description | Enzaplatovir (BTA-585, BTA-C585) is an orally bioavailable RSV fusion protein inhibitor for the treatment of respiratory syncytial virus infections. RSV Infection Phase 2 Discontinued |
---|---|
References | References View Related Products by Target RSV RSV Infection |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 663.0±55.0 °C at 760 mmHg |
Molecular Formula | C20H19N5O3 |
Molecular Weight | 377.397 |
Flash Point | 354.8±31.5 °C |
Exact Mass | 377.148804 |
LogP | -0.43 |
Vapour Pressure | 0.0±2.0 mmHg at 25°C |
Index of Refraction | 1.731 |